Background: Oral squamous cell carcinoma (OSCC) has emerged as one of the major malignant tumors of the head and neck cancers. However, little is known about the molecular mechanism behind tumorigenesis of OSCC. The aim of this study was to identify cancer-associated proteins by comparing the proteomes of OSCC and adjacent non-cancerous-matched tissues (NCMTs). Methods: We used two-dimensional electrophoresis coupled with mass spectrometry to identify differentially expressed proteins. Later we carried out MTT assay and transwell-based migration assay to study proliferation and migration of calreticulin knockdown OSCC cells, respectively. Finally, we conducted immunohistochemistry (IHC) to reveal calreticulin expression in OSCC and NCMT sections and analyze the correlations with multiple clinicopathological parameters. Results: After identification of the candidate proteins by LC/MS/MS, calreticulin was found to be upregulated in OSCC specimens. Calreticulin was differentially expressed in fresh tumor samples and six OSCC cell lines but not in adjacent NCMTs. Functional characterization of calreticulin by siRNA knockdown revealed its requirement for oral cancer cell proliferation and migration. Furthermore, using oral tissue microarray and IHC, we demonstrated that the positive staining of calreticulin in tumor specimens (99 of 103) was significantly higher than that in NCMTs (29 of 92) (P < 0.001). More importantly, we found that the intensity of calreticulin expression was positively correlated with various clinicopathological parameters including larger tumor size (T) (P = 0.0241), lower degree of tumor differentiation (P = 0.0007) and extracapsular spread (ECS) (P = 0.01). Conclusions: Together, our data suggest that calreticulin could play a key role in oral cancer development and could be a prognostic biomarker for OSCC patients. Background: Human papillomavirus (HPV) status is a strong and independent favorable prognostic factor for survival in tonsilar squamous cell cancer (TSCC). The reason for the improved survival in HPV-associated TSCC is unclear. Recently, activation of immune surveillance mechanism against non-self Ag is postulated to one of the reasonable causes as favorable prognosis of HPV associated with TSCC. Methods: We reviewed the medical records of histologically confirmed locally advanced TSCC patients, curatively treated in Asan Medical Center from January 2000 to December 2008. The immunohistochemistry (IHC) assays for p16 and FOXP3 were done in TSCC pafaffin-embedded samples. Results: We identified 79 patients who met the inclusion criteria. The median age was 54 years (range 32-76) and 16 (20%) patients were stage III and the others were all stage IV. With the median follow-up of 62.9 months (95% CI, 59.2-66.7), 63 (80%) were HPV-positive with p16 overexpression, and 38 (48%) were Treg-positive with FOXP3. Treg involvement was significantly related to HPV-positive status (P = 0.011). The result was the same after adjustment of age, T&N stage, smoking exposure and alcohol consumption. (Odd ratio = 6.54, 95% CI 1.58-27.1, P = 0.01.) Five-year overall survival (OS) rate in HPV-positive group was significantly higher than that of HPV-negative group (78% and 63%, hazard ratio (HR) = 0.347, 95% CI 0.14-0.87, P = 0.025), and 5-year OS of Treg-positive group was also higher than that of Treg-negative group (89% and 61%, HR = 0.158, 95% CI 0.05-0.53, P = 0.003). In multivariate analysis, the Treg status was an independent prognostic factor (HR = 0.11, 95% CI 0.03-0.40, P = 0.001), as well as HPV status (HR = 0.28, 95% CI 0.10-0.78, P = 0.016). Conclusions: HPV positivity was associated with Treg positivity in TSCC and both were found to be favourable prognostic factors for survival. Background: In this study, afatinib (A) (BIBW 2992), an oral, irreversible ErbB Family Blocker was compared with cetuximab (C) in patients ( patients) with recurrent/metastatic (R/M) HNSCC after platinum-based therapy failure. Methods: Eligible patients were randomized to A 50 mg/day or C 400 mg/m
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Tumor genetic analysis and circulating cytokine and angiogenic factors (CAF) analysis were carried out. Results: Fifty-nine patients were enrolled (med age: 52; male: 63%) and are evaluable for response. Fifty-four percent of patients required a dose reduction for management of toxicity, and 22% were withdrawn from therapy due to toxicity. The most common treatment-related adverse events were proteinuria 58% (gr 3: 2%), diarrhea 56% (gr 3: 5%), hypertension 48% (gr 3: 7%), fatigue 44% (gr 3: 5%), decreased appetite 41% (gr 3: 5%), nausea 34% (gr 3: 0), and weight decreased 32% (gr 3: 3%). No gr 4 events were reported for these event categories. Confirmed PRs were observed in 21 patients (RR: 36%, 95% CI: 24-49) based on independent imaging review (IIR) and 29 patients (RR: 49%, 95% CI: 36-62) based on investigator assessment. For patients who received prior VEGFR-directed treatment (n = 26) RR = 35% (IIR); with no prior VEGFR-directed treatment (n = 33) RR = 36 % (IIR). Median PFS by IRR is 9.0 months (95% CI: 7.0-) (based on minimum 8 months f/u, 46% events observed). There was no clear difference in the treatment response between RET-mutant (RET-mu) and RET-wild-type (RET-wt) patients. Low baseline levels of ANG2, sTie-2, HGF and IL-8 were associated with greater tumor shrinkage and prolonged PFS, whereas high baseline levels of VEGF and sVEGFR3 were associated with greater tumor shrinkage. Conclusions: Lenvatinib administered orally at a dose of 24 mg once daily to patients with MTC is associated with manageable toxicity and an RR of 36%, identifying lenvatinib as a promising new potential therapeutic agent for treating patients affected with this disease. 
Kanagawa Cancer Center
Background: To evaluate the efficacy and safety of chemoradiotherapy (CRT) concurrent with S-1 plus cisplatin in patients with unresectable locally advanced SCCHN. Methods: Eligibility criteria included histologically proven SCCHN with unresectable locally advanced lesions, PS 0-1, age 20-75, and no prior treatment. Chemotherapy consisted of administration of S-1 twice daily on days 1-14 at 60 mg/m 2 /day, and cisplatin at 20 mg/m 2 /day on days 8-11, repeated twice at a 5-week interval. Single daily radiation of 70 Gy in 35 fractions was given concurrently starting on day 1. For patients achieving an objective response after CRT, two additional cycles of chemotherapy were administered. The primary end point was clinical complete response rate (% CR), which was the proportion of complete response (CR) and good partial response (good PR). Good PR was defined as remaining tissue with tumor shrinkage, which was not regarded as residual tumor but rather as scar material. The planned sample size was 45 patients, which was calculated by SWOG's two-stage attained design based on an expected %CR of 60% and a threshold of 45%, with a one-sided alpha of 0.1 and a power of 0.9. Results: From July 2008 to July 2010, 45 eligible subjects were accrued, including 43 males, with median age 63 years, ECOG PS 0/1 (36/9), oropharynx/hypopharynx/ larynx (26/15/4), T1/T2/T3/T4a/T4b (1/11/7/17/9) and N0/N2a/N2b/N2c/N3 (2/3/ 10/24/6). %CR was 64.4% (8 CR, 21 good PR) on central review. After a median follow-up of 1.56 years, 1-year local progression-free survival was 77.8%, with 1-year progression-free survival of 70.9%, 1-year overall survival of 93.3% and 1-year time to treatment failure of 57.6%. Grade 3 or 4 toxicity included mucositis (46.7%), dysphagia (46.7%), anorexia (42.2%), radiation dermatitis (26.7%), neutropenia (26.7%) and febrile neutropenia (4.4%). No treatment-related deaths were observed. Conclusion: This combination showed promising efficacy with acceptable toxic effects. Further investigation in a phase III trial is planned. In recent years, several treatment principles have been firmly established for the treatment of a majority of patients with locoregionally advanced head and neck cancer (HNC). These include (i) therapies are administered with curative intent and (ii) organ preservation is pursued whenever possible. In order to achieve these goals, several tools have emerged as evidence-based approaches. Among these are concomitant chemoradiotherapy, usually with cisplatin as radiation sensitizer, as well as induction chemotherapy with the combination of cisplatin, docetaxel and fluorouracil being best supported by randomized clinical trials. It is unclear which of these approaches might be superior, although concurrent chemoradiotherapy continues to have the most abundant database to support its use. Current questions are whether or not induction chemotherapy and concomitant chemoradiotherapy should be combined in sequence. A recent randomized trial comparing concomitant chemoradiotherapy versus induction chemotherapy followed by concurrent chemoradiotherapy has been completed and results will be available this spring. There are also questions how to best treat patients with HPV-related HNC. It is possible that less intensive treatment might lead to similar cure rates as the current standard treatment approach. Furthermore, the integration of novel molecular diagnostics and therapeutic agents is under investigation.
